Fulphila: The First FDA-Approved Biosimilar for Neulasta

Brand: Fulphila (pegfilgrastim-jmdb), Injection
Parent Company: Mylan
Drug Type: Prescription
Drug Category: Oncology
Campaign: now-approved
Targeting: HCPs
Patient Website:
HCP Website: http://www.fulphila.com/